Momelotinib versus Continued Ruxolitinib or Best Available Therapy in JAK Inhibitor-Experienced Patients with Myelofibrosis and Anemia: Subgroup Analysis of SIMPLIFY-2.
Claire N HarrisonAlessandro M VannucchiChristian RecherFrancesco PassamontiAaron T GerdsJuan Carlos Hernandez-BoludaAbdulraheem YacoubShireen SirhanCatherine EllisBharat PatelBryan StrouseUwe PlatzbeckerPublished in: Advances in therapy (2024)
ClinicalTrials.gov: NCT02101268.